ES2149233T3 - 1,1-dioxo-2h-1,2-benzotiazinoilguanidinas sustituidas con efecto inhibidor del intercambio na+/h+. - Google Patents

1,1-dioxo-2h-1,2-benzotiazinoilguanidinas sustituidas con efecto inhibidor del intercambio na+/h+.

Info

Publication number
ES2149233T3
ES2149233T3 ES94120069T ES94120069T ES2149233T3 ES 2149233 T3 ES2149233 T3 ES 2149233T3 ES 94120069 T ES94120069 T ES 94120069T ES 94120069 T ES94120069 T ES 94120069T ES 2149233 T3 ES2149233 T3 ES 2149233T3
Authority
ES
Spain
Prior art keywords
benzotiazinoilguanidines
dioxo
substituted
exchange
inhibitor effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94120069T
Other languages
English (en)
Inventor
Andreas Dr Weichert
Heinz-Werner Dr Kleemann
Hans-Jochen Dr Lang
Jan-Robert Dr Schwark
Udo Dr Albus
Wolfgang Dr Scholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2149233T3 publication Critical patent/ES2149233T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

SE DESCRIBE ACILGUANIDINAS I CON X SIGNIFICANDO CARBONIL O SULFONIL; R(1) ES IGUAL A H, (CICLOALQUIL), FENIL; R(2) ES IGUAL A H, ALQUIL, ASI COMO SUS SALES TOLERABLES FARMACOLOGICAMENTE. SE OBTIENEN MEDIANTE TRANSFORMACION DE UN COMPUESTO II CON GUANIDINA. LOS COMPUESTOS NO TIENEN NINGUNA PROPIEDAD SALIDIURETICA NO DESEADA, SIN EMBARGO POSEEN BUENAS PROPIEDADES ANTIARRITMICAS. PUEDEN SER UTILIZADAS COMO CONSECUENCIA DE LA INHIBICION DE LOS MECANISMOS DE INTERCAMBIO NA+/H+ CELULARES PARA TRATAMIENTO DE TODOS LOS DAÑOS AGUDOS O CRONICOS DESENCADENADOS POR ISQUEMIA.
ES94120069T 1993-12-24 1994-12-19 1,1-dioxo-2h-1,2-benzotiazinoilguanidinas sustituidas con efecto inhibidor del intercambio na+/h+. Expired - Lifetime ES2149233T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4344550A DE4344550A1 (de) 1993-12-24 1993-12-24 Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen

Publications (1)

Publication Number Publication Date
ES2149233T3 true ES2149233T3 (es) 2000-11-01

Family

ID=6506276

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94120069T Expired - Lifetime ES2149233T3 (es) 1993-12-24 1994-12-19 1,1-dioxo-2h-1,2-benzotiazinoilguanidinas sustituidas con efecto inhibidor del intercambio na+/h+.

Country Status (20)

Country Link
US (1) US5547953A (es)
EP (1) EP0659748B1 (es)
JP (1) JP3790559B2 (es)
KR (2) KR100360127B1 (es)
CN (1) CN1053899C (es)
AT (1) ATE194605T1 (es)
AU (1) AU683320B2 (es)
CA (1) CA2138466A1 (es)
DE (2) DE4344550A1 (es)
DK (1) DK0659748T3 (es)
ES (1) ES2149233T3 (es)
FI (1) FI946039L (es)
GR (1) GR3034335T3 (es)
HU (1) HU222524B1 (es)
IL (1) IL112114A (es)
NO (1) NO304787B1 (es)
NZ (2) NZ270264A (es)
PT (1) PT659748E (es)
TW (1) TW504505B (es)
ZA (1) ZA9410242B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0765867A1 (de) * 1995-09-27 1997-04-02 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
DE19548708A1 (de) * 1995-12-23 1997-06-26 Merck Patent Gmbh Cyclische Sulfone
NZ314105A (en) * 1996-02-02 1997-12-19 Sumitomo Pharma Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
JPH10152481A (ja) * 1996-09-25 1998-06-09 Kanebo Ltd ベンゾ［１，４］チアジン誘導体およびそれからなる医薬
US6436927B1 (en) 1997-02-12 2002-08-20 Smithkline Beecham Corporation IL-8 receptor antagonists
ES2224365T3 (es) * 1997-02-12 2005-03-01 Smithkline Beecham Corporation Antagonistas de receptores de il-8.
WO1998039300A1 (en) 1997-03-06 1998-09-11 Toa Eiyo Ltd. CYCLOALKA[b]PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND DRUGS CONTAINING THE SAME
JP2002502414A (ja) * 1997-06-02 2002-01-22 藤沢薬品工業株式会社 細胞中のＮａ▲上＋▼／Ｈ▲上＋▼交換の阻害剤としてのグアニジン誘導体
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163914A1 (de) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
WO2006044645A2 (en) 2004-10-13 2006-04-27 Adolor Corporation Sulfamoyl benzamides and methods of their use
DK2648511T3 (en) 2010-12-08 2017-09-18 Lycera Corp PYRAZOLYLGUANIDINE-F1F0 ATPASE INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF
US9169199B2 (en) 2010-12-08 2015-10-27 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
MX2013006398A (es) 2010-12-08 2013-12-02 Lycera Corp Inhibidores de f1f0-atpasas de tipo piridonilguanidina y usos terapeúticos.
US9221814B2 (en) 2012-06-08 2015-12-29 Lycera Corporation Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof
US9580391B2 (en) 2012-06-08 2017-02-28 Lycera Corporation Saturated acyl guanidine for inhibition of F1F0-ATPase
US9920012B2 (en) 2012-06-08 2018-03-20 Lycera Corporation Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
MX2016007445A (es) 2013-12-10 2016-09-09 Lycera Corp Inhibidores de f1f0-atpasa de trifluorometil pirazolil guanidina y usos terapeuticos de los mismos.
EP3080088B1 (en) 2013-12-10 2019-07-31 Lycera Corporation Alkylpyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
WO2015089152A1 (en) 2013-12-10 2015-06-18 Lycera Corporation N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780027A (en) * 1970-04-29 1973-12-18 Merck & Co Inc Anthranilic acid derivatives
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
DK0556674T3 (da) * 1992-02-15 1996-10-14 Hoechst Ag 3,5-Substituerede benzoylguanidiner med antiarytmisk virkning og inhiberende virkning på celleproliferation
EP0589336B1 (de) * 1992-09-22 1997-01-08 Hoechst Aktiengesellschaft Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika
ES2152938T3 (es) * 1992-09-28 2001-02-16 Hoechst Ag 1(2h)-isoquinolinas sustituidas antiarritmicas y cardioprotectoras, procedimiento para su produccion, medicamento que las contiene y su uso para la produccion de un medicamento para combatir fallos cardiacos.
TW250479B (es) * 1992-12-15 1995-07-01 Hoechst Ag

Also Published As

Publication number Publication date
DE59409439D1 (de) 2000-08-17
NO945015D0 (no) 1994-12-23
CN1107840A (zh) 1995-09-06
FI946039A7 (fi) 1995-06-25
US5547953A (en) 1996-08-20
NZ272846A (en) 1996-02-27
DK0659748T3 (da) 2000-10-02
IL112114A0 (en) 1995-03-15
NO304787B1 (no) 1999-02-15
FI946039A0 (fi) 1994-12-22
AU8170094A (en) 1995-06-29
KR100360127B1 (ko) 2003-04-23
KR100353339B1 (ko) 2002-09-19
GR3034335T3 (en) 2000-12-29
NO945015L (no) 1995-06-26
FI946039L (fi) 1995-06-25
DE4344550A1 (de) 1995-06-29
PT659748E (pt) 2000-11-30
ATE194605T1 (de) 2000-07-15
TW504505B (en) 2002-10-01
CA2138466A1 (en) 1995-06-25
NZ270264A (en) 1996-02-27
IL112114A (en) 2001-06-14
EP0659748A1 (de) 1995-06-28
HU222524B1 (hu) 2003-08-28
HU9403759D0 (en) 1995-02-28
EP0659748B1 (de) 2000-07-12
JPH07206823A (ja) 1995-08-08
KR950017981A (ko) 1995-07-22
HUT72749A (en) 1996-05-28
JP3790559B2 (ja) 2006-06-28
ZA9410242B (en) 1995-08-02
AU683320B2 (en) 1997-11-06
CN1053899C (zh) 2000-06-28

Similar Documents

Publication Publication Date Title
ES2149233T3 (es) 1,1-dioxo-2h-1,2-benzotiazinoilguanidinas sustituidas con efecto inhibidor del intercambio na+/h+.
AR246755A1 (es) Una composicion para el tratamiento de las superficies de los suelos.
GT199900022A (es) Compuestos para el tratamiento de la isquemia
ES2062395T3 (es) Nuevos compuestos de bencimidazol y su uso.
NO972922L (no) Preparater og metoder for å redusere hudirritasjon
BR8307166A (pt) Composicao microbicida,processo para o combate de microorganismos e emprego
DK0924201T3 (da) Tricyclisk substitueret pyrazolylbenzensulfonamider og deres anvendelse som cyclooxygenase II-inhibitorer
ES375496A1 (es) Procedimiento para la preparacion de colorantes reactivos.
AR246497A1 (es) Metodo para inhibir el crecimiento y la proliferacion de microorganismos.
NO970495L (no) Aryltioforbindelser som anti-bakterielle og antivirale midler
DK0665844T3 (da) Substituerede benzylaminoquinuclidinforbindelser som antagonister af substans P
ES2167495T3 (es) Composicion de caucho vulcanizado.
GB1222254A (en) Aromatic sulphonamide carboxylic acids and salts thereof and use of the salts as metal-working agents
EA200000728A1 (ru) Замещенные 2-бензиламино-2-фенилацетамидные соединения
DK161896C (da) Anvendelse af korrosionsinhibitorer i vandige systemer
MX9400194A (es) Materiales fototermograficos.
AR240813A2 (es) N-fenilsulfonil-n'-pirimidinilureas, procedimiento para su preparacion, composiciones que las contienen e intermediarios para uso exclusivo en dicho procedimiento
PE66298A1 (es) Inhibicion de las metaloproteasas de matriz por compuestos de fenetileno sustituido
ES2164151T3 (es) N-(indol-2-carbonil)glicinamidas sustituidas y derivados como inhibidores de la glucogeno fosforilasa.
FI960588A0 (fi) Mikrobisideina käytettäviä tiokarbamoyyliyhdisteitä
YU41702A (sh) Nitro-sulfobenzamidi
PE69199A1 (es) Derivados de arilsecocoladieno
EP0626369A4 (en) BENZENE SULPHONAMIDE DERIVATIVES.
EA200200416A1 (ru) Кристаллы ингибитора натрий-водородного обмена 1 типа
DK0796257T3 (da) Malonsyrebaserede matrixmetalloproteinase-inhibitorer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 659748

Country of ref document: ES